Preparation for Attaching to Teeth or Surrounding Part of Teeth

ABSTRACT

The present invention provides a preparation for attaching to teeth or tooth peripheries, which comprises a malleable oral composition and an active ingredient for intra-oral delivery. Further, the present invention provides a preparation for attaching to teeth or tooth peripheries, which comprises an oral composition in a hardening ointment-phase and an active ingredient for intra-oral delivery. The preparation of the present invention may give high adhesive force to the desired site in spite of gaps between teeth or curves of teeth. The preparation of the present invention having high adhesive force increases the time of adhesion to a target site in the oral cavity, and thus may be advantageous in achieving an intended effect.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.15/778,127 filed on May 22, 2018, which is a national phase entry under35 U.S.C. § 371 of International Application No. PCT/KR2016/012934,filed Nov. 10, 2016, which claims priority to Korean Patent ApplicationNo. 10-2015-0164928, filed Nov. 24, 2015, and Korean Patent ApplicationNo. 10-2015-0171541, filed Dec. 3, 2015, the disclosures of which areincorporated herein by reference.

TECHNICAL FIELD

The present invention relates to a preparation for delivering a druginto the oral cavity, and more specifically, it relates to a novel formof an oral preparation, which can effectively deliver an activeingredient to the desired site in the oral cavity.

BACKGROUND OF THE INVENTION

In order to deliver an oral active ingredient into the oral cavity, thecontact time with an active ingredient and the delivery amount play animportant role.

Paste formulations such as toothpaste have a disadvantage that it isdifficult to provide sufficient contact time at the target site due toinsufficient viscosity and high solubility, and mouth trays intended forintraoral drug delivery have a disadvantage that they have a strongsense of foreign body and difficult to deliver a drug locally due totheir shape characteristics. Patch type or strip type is thin, so it isdifficult to deliver sufficient amount of an active ingredient, andflexibility is low, so there is a disadvantage that it is difficult tobe adhered to gaps between teeth, boundary area between gums and teeth,and the like.

In order to solve the adhesion problem to the gaps between teeth,boundary area between gums and teeth and the like, Korean Patent No.10-0623859 developed a delivery system for a tooth whitening componentusing in situ gelling, but there was a disadvantage that it is necessaryto use a separate backing layer because it is highly flowable whenapplied to the tooth surface. Further, WO 2003/037276 discloses apreparation to be sprayed in the oral cavity due to its low initialviscosity, but there was a problem that the difference between thenormal storage temperature (especially in summer) and the temperature inthe oral cavity is small and it is difficult to remove it because thephase transition does not occur rapidly unless it is applied very thin.

U.S. Pat. No. 5,989,569 discloses about applying a drug to the surfaceof a strip and delivering the drug by pressure, but there were problemsthat the active ingredient is temporarily released because the drug isapplied on the surface of the strip and adhered to teeth as it is, andit may cause strong stimulus in the gums around the teeth. Further,there was a disadvantage that physical properties, in particular,flexibility, of the drug to be applied are different from those of thestrip, and therefore, adhesion to gaps between teeth is difficult.

The inventors of the present invention have studied for a long time todevelop a novel form of a preparation, which can effectively deliver adrug into the oral cavity with convenience of use, thereby completingthe present invention.

SUMMARY OF THE INVENTION

In order to solve the above problems, the present invention provides apreparation for delivering an active ingredient whose physicalproperties are changed before attachment to teeth and after a period oftime after the attachment.

Further, the present invention provides a preparation in a form that canbe freely changed before use, and can be adhered well to gaps betweenteeth or a boundary area between gums and teeth.

Further, the present invention provides a novel form of an oralpreparation having excellent feeling of use, which can be convenientlyused without any feeling of being stained or sticky in the hands whenattached to teeth or tooth peripheries.

These and other objects and advantages of the present invention may beunderstood from the following detailed description and will become morefully apparent from the exemplary embodiments of the present invention.Also, it will be easily understood that the objects and advantages ofthe present invention may be realized by the means shown in the appendedclaims and combinations thereof.

Definition

The term ‘tooth peripheries’ used herein is generally a conceptinvolving a region represented by gums, and may be used to meanincluding all of the mucosal regions around teeth. The tooth peripheriescan be used to mean covering the region where an active ingredient forintra-oral delivery can be delivered together with the teeth when thepreparation is applied to the teeth in the structure of the preparation.Herein, ‘teeth or tooth peripheries’ is used together with ‘teeth’, andit may be understood herein to include both the teeth and the toothperipheries even if it is described only as ‘teeth’.

The term ‘oral composition in a hardening ointment-phase’ used hereinmeans an oral composition that does not have a certain shape beforeadhered to teeth, has an ointment phase of free-shape transformation,gradually loses its fluidity, and its shape is fixed. Namely, it meansan ointment-type oral composition, which has a characteristic that thepreparation of the present invention is ointment type when thepreparation is applied to teeth or tooth peripheries, after application,its viscosity increases up to the point of adhesion, and it hardens atthe point when it is removed from teeth after adhesion.

The ‘hardening ointment-phase’ preparation may mean a preparation thatis a semi-solid-type ointment such as dough or clay after application,but is molded with external force such as heat or pressure over time,gradually loses its moldability and hardens, and finally permanentlytransformed.

The term ‘hardening’ used herein may include not only hardening by theformation of a network structure such as an ionic crosslinked structurelike an egg-box model but also a decrease in fluidity accompanied by aprogress of polymerization reaction by light or a catalyst, and may meana state of hardly hardening due to various factors such as degree ofabsorption of water and degree of exposure to air, and no further shapetransformation.

The term ‘malleability’ used herein may mean that the preparation of thepresent invention has shape transformability or can have moldability byexternal pressure. It also mean that the preparation is sufficientlyflexible and it is possible to transform to such a degree that when thepreparation is adhered in the mouth, it can be completely adhered togaps between teeth or the fine portion between teeth and gums.

Herein, not only the case that the preparation is stretched to the leftand right but also the case that when it is placed on a flat surface andpressed with a certain force, the preparation is transformed bystretching in all directions can be included in the range ofmalleability. Further, any form causing change in appearance can beincluded in the range of malleability. With malleability, an object canbe compressed or the area can be widened in a certain hardness range.

The term ‘hardness’ used herein may mean the amount of force required tocompress the preparation. Hardness of the preparation of the presentinvention is measured at compression test mode of Stable Micro System TAXT Plus. After filling 20 g of the preparation into a 50 mL beaker, a 20mm diameter aluminum probe for hardness measurement is set, and thenhardness is measured with test speed of 1.5 mm/s, distance as targetmode and distance of 10 mm. Hardness is understood as the peak value ofthe first cycle calculated. The unit can be expressed as g (g force).

The term ‘compressibility’ used herein may mean the force applied untiljust before the preparation is broken, cut or destroyed while it iscompressed. Compressibility of the preparation of the present inventionis measured at compression test mode of Stable Micro System TA XT Plus.After filling 20 g of the preparation into a 50 mL beaker, a 20 mmdiameter aluminum probe for compressibility measurement is set, and thencompressibility is measured with test speed of 1.5 mm/s, distance astarget mode and distance of 10 mm. Compressibility is understood as thearea value of the first cycle calculated. The unit can be expressed asgs (g force*sec).

The term ‘compressibility’ used herein may mean a characteristic thatwhen compressing the preparation, it can expand without breaking orcutting while its volume is reduced.

The term ‘elongation percentage’ used herein means the degree to whichthe preparation can be stretched in all directions when load is applied,such as when a preparation is compressed between rollers. The term‘elongation percentage’ used herein can be understood to mean “planestrain” unless otherwise specified. Good elongation percentage can beunderstood as having malleability.

Meaning of the term ‘applied to teeth’ used herein may include fromimmediately after application of the preparation to teeth to before thepreparation adhered to teeth after a user applies pressure to thepreparation. In the case of two-formulation type, the term ‘afterapplying the preparation’ in the present invention may mean afterapplying the mixture of the first formulation and the second formulationto teeth.

The term ‘when adhering the preparation to teeth’ in the presentinvention means the time of adhering the preparation to curves of teeth,gaps between teeth, or between teeth or gums by applying pressure aftera certain period of time after application of the preparation to teeth,and preferably, the adhesion may be understood to be about 10 min orless, preferably about 5 min or less, more preferably about 1 to 3 minor less after applying the preparation of the present invention toteeth.

The term ‘time of removal of the preparation’ in the present inventionmay mean the time that the drug is released from the oral cavity afterit is adhered to teeth or a surrounding tissue of teeth and then thepreparation is removed therefrom. Depending on the purpose and use ofthe preparation, and the release amount of the drug, but it may beremoved after 2 hr from attachment, but it may be removed within 30 min,more preferably within 10 min after adhered to teeth in view ofconvenience of use. Hardness of the preparation at the time of removalmay be equal to the time at which the preparation is applied to teethand the time at which the preparation is adhered to teeth, and hardnessof the preparation at the time of removal may be increased.

The term ‘preparation’ used herein means to a product made by processingthe active ingredient to ensure its therapeutic effect without affectingeffectiveness of the active ingredient.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a preparation for attaching to teeth ortooth peripheries, which comprises an oral composition in a hardeningointment-phase, and an active ingredient for intra-oral delivery. Thepresent inventors have studied on a drug delivery system capable ofdelivering an active ingredient into the oral cavity, thereby suggestinga novel form of a drug delivery system and a novel method for deliveringthe active ingredient into the oral cavity using such a system.

The present inventors have studied for a long time on a novel drugdelivery system capable of effectively delivering an active ingredientto specific sites in the oral cavity (for example, sites requiring toothwhitening, sites of oral inflammation, sites of periodontal disease,etc.). As a result, a novel form of an oral preparation, which can beconveniently applied to teeth or a mucosal region in the oral cavity,and can be adhered well to a curvy region and gaps between teeth so asto increase the drug reach rate at the desired site, has been developed.

One embodiment of the present invention provides a preparation forattaching to teeth or tooth peripheries, wherein an oral composition ina hardening ointment-phase and an active ingredient for intra-oraldelivery are mixed. For example, the active ingredient can behomogeneously dispersed in the oral composition, and the case that theingredient is inhomogeneously dispersed is also included in the mixingof the present invention.

According to one embodiment of the present invention, preparation of thepresent invention may substantially lose moldability at the time of thefinal removal, and preferably, at the time of the final removal,viscosity may be 5,000 cps or higher and moldability may be lost. Thepreparation may have viscosity of 5000 cPs or higher, preferably 10,000cPs or higher, more preferably 200,000 cPs or higher, which is measuredby using Brookfield viscometer equipped with No. 6, 7 spindles at atemperature of 20° C. (room temperature), 5 to 20 rpm, at the time ofremoval of the preparation after the preparation is applied to teeth ortooth peripheries and then the drug is released. Viscosity at the timeof the final removal of the preparation may vary depending on the typeand amount of a phase transition material, a phase transition auxiliarymaterial, a material for helping attachment of the phase transitionmaterial and the like, contained in the preparation, and preferably,viscosity measured at the time of removal may be 5,000 cPs or higher and104,000,000 cPs or less.

According to one embodiment of the present invention, the viscosity ofthe preparation attached to teeth, measured at the time of removal, maybe increased two folds or more, preferably three folds or more, morepreferably five folds or more, compared to the viscosity measured at thetime of application of the preparation to teeth or tooth peripheries.

According to another embodiment of the present invention, the viscosityof the preparation of the present invention, measured at the time ofremoval, may be 5,000 cPs or higher, and may have a value two folds ormore than the viscosity measured at the time of application to teeth.

The oral composition in a hardening ointment-phase contained in thepreparation of the present invention may comprise a phase transitionmaterial, a phase transition auxiliary material, an attachment-enhancingmaterial of the phase transition composition, and a material for helpingdrug release.

The phase transition material is a substance that causes hardening ofthe oral composition in a hardening ointment-phase. It may becarrageenan, pectin, xyloglucan, gellan gum, ammonium alginate,magnesium alginate, potassium alginate, sodium alginate, lithiumalginate, chitosan, poly-lactic acid (poly(D,L-lactic acid)),polylactide-co-glycolide (poly(DL-lactide-co-glycolide)),poly-caprolactone, polyacrylic acid (carbopol), polyvinylacetal diethylaminoacetate (AEA), hydroxypropylmethyl cellulose, poly(methacrylicacid)-poly(ethylene glycol), poly(D,L-lactide)-block-poly(ethyleneglycol)-block-poly(D,L-lactide), PEG-oligoglycolyl-acrylate,poly(N-isopropyl acrylamide), sucrose acetate isobutyrate, polyvinylalcohol, glyceryl monooleate, glyceryl monolinoleate, glycerylmonoarachidonate, glyceryl monostearate and the like alone or acombination of two or more thereof. Any material that can be used as aphase transition material in the art can be used and is not limited tothe above examples.

The hardening ointment-phase composition may comprise theattachment-enhancing material of the phase transition composition, thatis adhesive to teeth or has adhesiveness retention force; and that iswell compatible with the phase transition material. For example, thematerial may be precipitated silica for thickening, colloidal siliconedioxide, polyvinyl pyrrolidone, poly methyl vinyl ether and maleic acidcopolymers (gantrez), shellac, rosin, poloxamer, hyaluronic acid,acrylate copolymer (Eudragit L-100, L-100,55), hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), polyacrylic acid,polyethylene glycol, ethyl cellulose or a mixture thereof, but notlimited thereto. Preferably, it may be hydroxypropyl methyl cellulose(HPMC) or ethyl cellulose or a mixture thereof. Such polymer can be usedby dissolving thereof in water or a solvent (for example, ethanol), butcrosslinked polymers also can be used. For example, the polymer may becrosslinked polyacrylic acid, or crosslinked polyvinyl pyrrolidone, andsuch crosslinked polymer can be used alone or in combination with anon-crosslinked polymer. In the case of a polymer obtained bycross-linking polymers having excellent adhesive force to teeth or gums,it is advantageous to improve adhesion of the composition as well as toimprove the residuality because it is not dissolved in water or ethanolwhile exhibiting adhesive force after absorbing water.

The phase transition auxiliary material is a substance that can inducephase transition, control phase transition rate and adjust a degree ofphase transition, and a calcium ion can be used. It is preferable thatthe calcium ion is water-soluble, but a calcium ion, which is insolublein neutral or alkaline condition but can easily be converted intowater-soluble in an acidic condition, also can be used. For example, thephase transition auxiliary material may be at least one selected from: acalcium ion source of calcium carbonate, calcium phosphate dibasic(CaHPO₄), barium carbonate, zinc carbonate, calcium chloride, calciumlactate, calcium citrate, calcium aspartate, calcium saccharate, calciumoxovalerate, calcium gluconate, calcium lactobionate and calciumlactogluconate; a chelating agent such as barium carbonate, zinccarbonate, sodium bicarbonate, sodium carbonate, tetraborate,tripolyphosphate, ethylenediamine tetraacetic acid, tetrasodiumpyrophosphate, sodium acid pyrophosphate, Sporix (acidic sodiummetaphosphate) and the like; acetic acid, malic acid, lactic acid,gluconic acid, ascorbic acid or a mixture thereof, or a salt thereof;and NaOH, KOH or a mixture thereof.

The phase transition material, the phase transition auxiliary materialand the attachment-enhancing material of the phase transition materialcontained in the hardening ointment-phase composition are exemplarilylisted, but not necessarily limited the above examples. According toanother embodiment of the present invention, depending on the mechanism,the phase transition material, the phase transition auxiliary materialand the attachment-enhancing material can be used indiscriminately. Forexample, if the phase transition material is polyvinyl alcohol, thephase transition auxiliary material may be tetraborate, and the materialfor enhancing adhesive force may be alginate or colloidal silica. Inanother embodiment, if the phase transition material is alginate, thephase transition auxiliary material may be calcium, and the material forenhancing adhesive force may be methyl vinyl ether and maleic acidcopolymer (gantrez).

The material for helping drug release may be any material that can forma channel, a porous structure or bubble (foam) in the formulation. Forexample, in the case that the preparation is consisting of twoformulations of the first formulation and the second formulation, oneformulation contains an acid and the other contains a base, so thatbubbles are formed in the formulation when the two formulations meet toform a hardening ointment-phase. Namely, the first formulation containsacetic, lactic, malic, gluconic, ascorbic acids and the like or awater-soluble salt thereof, e.g., sodium citrate, and the secondformulation contains any base selected from the group consisting ofsodium hydroxide (NaOH), potassium hydroxide (KOH), sodium bicarbonate(baking soda) and sodium carbonate. Preferably, the acid may be aceticacid, and the base may be sodium carbonate, and more preferably, thosemay be sodium citrate and sodium bicarbonate, which are an acid and abase mainly used in a toothpaste.

The active ingredient may include, for example, ingredients that canimprove oral symptoms, and for example, it may be an ingredient fortooth whitening, an ingredient for preventing cavity containing afluoride ion source, an ingredient for inhibiting tartar formation, ananti-inflammatory ingredient, an anti-bacterial ingredient, othervitamins, mineral ingredients and the like. Further, it may also includeingredients for improving sensitive teeth and for relieving itssymptoms, and the like. More specifically, for example, it may include:at least one fluoride ion source selected from the group consisting ofsodium fluoride, stannous fluoride, indium fluoride, amine fluoride andsodium monofluorophosphate; a reminerlaization agent containinghydroxyapatite; and an ingredient for tooth whitening selected fromhydrogen peroxide, carbamide peroxide, calcium peroxide, perborate,percarbonate, peroxyacid, persulfate, calcium chloride, barium chloride,magnesium chloride, lithium chloride, sodium chloride or a mixturethereof. For enhancing whitening effect, a condensed phosphate can beused together with peroxides. The condensed phosphate, which can beused, may be at least one of tetrasodium pyrophosphate (TSPP), sodiumacid pyrophosphate (SAPP), sodium tripolyphosphate (STP), sodiumpotassium pyrophosphate, tetrapotassium pyrophosphate, acidic sodiummetaphosphate and acidic sodium polyphosphate, and it may be usedtogether with peroxides. Such condensed phosphate also can be used forremoving tartar or inhibiting tartar formation. Further, it can alsocontribute to the improvement of whitening effect by removing the metalwhich affects the stain formation of teeth as a chelating agent. Theactive ingredient may include an anti-bacterial agent includingtriclosan, chlorhexidine, alexidine, hexetidine, sanguinarine,benzalkonium chloride, salicylanilide, domiphen bromide, cetylpyridiniumchloride (CPC), tetradecylpyridinium chloride (TPC) or a mixturethereof; an anti-inflammatory agent including aspirin, ketorolac,flurbiprofen, piroxicam, meclofenamic acid or a mixture thereof;thiamine, riboflavin, nicotinic acid, pantothenic acid, pyridoxine,biotin, folic acid, vitamin B12, lipoic acid, ascorbic acid, vitamin A,vitamin D, vitamin E, vitamin K or a mixture thereof; or a mixturethereof, but not limited thereto. Further, the drug effective forpreventing and improving periodontal diseases may be titrated extract ofZea Mays L. unsaponifiable fraction, Magnoliae Cortex, Myrrha, Rhatany,Chamomile, policresulen, titrated extract of Centella Asiatica, nutmegextract, dexpanthenol, β-sitosterol, acetyl salicylic acid and the likealone, or a mixture thereof of a certain mixing ratio. The ingredientfor improving and relieving sensitive teeth symptoms may be zincchloride, potassium phosphate, potassium diphosphate, calcium chloride,oxalic acid, potassium oxalate, ferric oxalate, vitamin E and the likealone, or a combination of two or more thereof.

According to one embodiment of the present invention, the preparationmay be one-formulation type, or two-formulation type consisting of thefirst formulation and the second formulation, and three or moreformulations may be mixed as required.

The first formulation and the second formulation of the two-formulationtype preparation are mixed and applied to teeth or tooth peripheries,and in order to apply the preparation to teeth or tooth peripheries, theviscosity of the preparation measured after mixing the first formulationand the second formulation may be increased, compared to before mixing.After mixing, it may have moldability like dough.

The two-formulation type preparation may contain the active ingredientin the first formulation, the second formulation or both of the firstformulation and the second formulation.

The two-formulation type preparation may selectively contain the phasetransition material, the phase transition auxiliary material and theattachment-enhancing material in the first formulation, the secondformulation or both of the first formulation and the second formulation.

For example, the two-formulation type preparation may contain magnesiumalginate as a phase transition material in the first formulation. Thetwo-formulation type preparation may contain calcium chloride as amaterial for helping hardening of the phase transition material, andhydroxypropyl cellulose as a material for helping attachment to teeth ortooth peripheries in the second formulation. In this case, the activeingredient may be appropriately contained in consideration ofcompatibility of the polymers contained in the first formulation and thesecond formulation, characteristics thereof and the like.

The preparation of the present invention may substantially losemoldability at the time of removal after attachment to teeth.Preferably, the time of removal may mean at 5 min to 3 hr, preferably 8min to 90 min after application to teeth or tooth peripheries. Forexample, it may be removed after 10 min, 30 min or 1 hr from attachment.

In another embodiment, the time of removal after attachment to teeth maybe, for example, the time at which the amount of the active ingredientcontained in the preparation becomes 30 wt % or less, based on the totalloaded weight of the drug at the beginning.

The substantially losing moldability means a hardening state in whichthe preparation loses physical properties such as dough and its shapetransformation is not possible at the time of removal of the preparationafter application. In one embodiment of the present invention,water-solubility of the preparation, measured at 32° C., 1 atm at astate of substantially losing moldability, may be 20 wt % or less,preferably 15 wt % or less, more preferably 10 wt % or less, and themost preferably 1 wt % to 10 wt %.

The preparation may further comprise a backing layer as required when itis attached to teeth or tooth peripheries. The backing layer may includea water-insoluble polymer, generally used in an oral film, and forexample, polyethylene (PE), polypropylene (PP), ethylene vinyl acetate(EVA), cellulose acetate phthalate, shellac, polyvinyl acetate, ethylcellulose, polymethyl methacrylate, methacryloylethylbetain/methacrylate copolymer (Yukaformer; Manufacturer: Mitsubishi),methacrylic acid copolymer (Eudragit L 100, Eudragit L 12,5, Eudragit L100-55, Eudragit L 30D-55), aminoalkyl methacrylate copolymer (EudragitE 100, Eudragit E 12,5, Eudragit RL 100, Eudragit RL 30D) and the likemay be used.

The present invention provides a preparation for attaching to teeth orteeth and gums around teeth, which comprises a malleable oralcomposition, and an active ingredient for intra-oral delivery. Thepresent inventors have studied on a drug delivery system capable ofdelivering an active ingredient into the oral cavity, thereby suggestinga novel form of a drug delivery system and a novel method for deliveringthe active ingredient into the oral cavity using such a system.

The present inventors have studied for a long time on a novel drugdelivery system capable of effectively delivering an active ingredientto specific sites in the oral cavity (for example, sites requiring toothwhitening, sites of oral inflammation, sites of periodontal disease,etc.). As a result, a novel form of an oral preparation, which canconveniently be applied to teeth or a mucosal region in the oral cavity,and can be adhered well to a curvy region and gaps between teeth so asto increase the drug reach rate at the desired site, has been developed.

One embodiment of the present invention provides a preparation forattaching to teeth or tooth peripheries, wherein a malleable oralcomposition and an active ingredient for intra-oral delivery are mixed.For example, the active ingredient can be homogeneously dispersed in theoral composition, and the case that the ingredient is inhomogeneouslydispersed is also included in the mixing of the present invention.

According to one embodiment of the present invention, the preparation ofthe present invention has semi-solid property at the same time, so thatit can be adhered to curves or gaps.

The preparation of the present invention may have a form such as doughor clay, and it can be applied to teeth or tooth peripheries as the formof an ointment.

The preparation of the present invention may have the initial hardnessin a range from 0.1 g to 20,000 g, preferably from 10 g to 12,000 g,measured at Compression mode of Texture Analyzer (TA), at the time ofattachment. When the initial hardness is within the above range, thepreparation can be easily adhered to gaps or curves of teeth.

The preparation may have the final hardness of 40,000 g or less,preferably 30,000 g or less, measured at Compression mode of TextureAnalyzer (TA), at the time of removal.

The preparation having the final hardness within the above range canachieve the desired effect (for example, effect of improving sensitiveteeth, tooth whitening effect, effect of preventing gingivitis and thelike) by smoothly releasing the drug, and can have excellent shapefixing force.

In another embodiment of the present invention, the preparation may havethe initial compressibility of 0.1 gs to 30,000 gs, preferably in arange from 10 gs to 20,000 gs, measured at Compression mode of TextureAnalyzer (TA). When the compressibility is within the above range, thepreparation can be easily adhered to gaps or curves of teeth.

The preparation may have the final compressibility of 50,000 gs or less,preferably 40,000 gs or less, measured at Compression mode of TextureAnalyzer (TA).

The preparation having the final compressibility within the above rangecan achieve the desired effect (for example, effect of improvingsensitive teeth, tooth whitening effect, effect of preventing gingivitisand the like) by smoothly releasing the drug, and can have excellentshape fixing force. Such shape fixing force can secure a sufficientcontact time to the site where the drug is required to reach, andtherefore, it can be more advantageous in achieving the desired effect.

The preparation according to one embodiment of the present invention mayhave malleability, which can increase length of the composition whenpressing the preparation with a force of 0.5 kgf/cm² or more, preferably1 kgf/cm² or more, at the beginning of attachment. Specifically, thepreparation may have elongation percentage of 120% or more, preferablyelongation percentage of 150% or more when pressing the preparation witha finger under conditions of standard relative humidity of 65% and 25°C., or when pressing with a pressure roller with a force of 0.5 kgf/cm²or more, preferably a force of 1 kgf/cm² or more. In another preferablyembodiment, the preparation may have the elongation percentage of 120%or more and 500% or less.

Further, the malleability of the preparation of the present inventionmay be around 10% of the elongation percentage change from the time ofapplication of the preparation to the teeth or tooth peripheries to thetime of removal of the preparation. For example, in one embodiment ofthe present invention, the oral preparation of the preparation, whereinthe first formulation containing PVA (polyvinyl alcohol) and the secondformulation containing Borax are mixed, may have the same value ofmalleability and elongation percentage. Namely, the malleability whichis measured at the time of application to the teeth surface, and theelongation percentage which is measured at the time of removal when thedrug release has progressed by 60% or more after a certain period oftime according to the method for measuring elongation percentage, i.e.,a sample of a certain weight is made at size of 1 cm² and the sample ispressed with a pressure roller at a pressure of 2 kgf/cm², are the sameas 150% and 150%, respectively.

The oral composition contained in the preparation of the presentinvention may comprise a phase transition material, a phase transitionauxiliary material, an attachment-enhancing material of the phasetransition composition, and a material for helping drug release.

The phase transition material is a substance which can cause cohesiveproperty to the oral composition. It may be carrageenan, pectin,xyloglucan, gellan gum, ammonium alginate, magnesium alginate, potassiumalginate, sodium alginate, lithium alginate, chitosan, poly-lactic acid(poly(D,L-lactic acid)), polylactide-co-glycolide(poly(DL-lactide-co-glycolide)), poly-caprolactone, polyacrylic acid(carbopol), polyvinylacetal diethyl aminoacetate (AEA),hydroxypropylmethyl cellulose, poly(methacrylic acid)-poly(ethyleneglycol), poly(D,L-lactide)-block-poly(ethyleneglycol)-block-poly(D,L-lactide), PEG-oligoglycolyl-acrylate,poly(N-isopropyl acrylamide), sucrose acetate isobutyrate, polyvinylalcohol, polyvinyl acetate, glyceryl monooleate, glyceryl monolinoleate,glyceryl monoarachidonate, glyceryl monostearate and the like alone, ora combination of two or more thereof, and any material that can be usedas a phase transition material in the art can be used, but not limitedto the above examples.

The malleable oral composition may comprise the attachment-enhancingmaterial of the phase transition composition, that is adhesive to teethor has adhesiveness retention force; and that is well compatible withthe phase transition material. For example, precipitated silica forthickening, colloidal silicone dioxide, polyvinyl pyrrolidone, polymethyl vinyl ether and maleic acid copolymers (gantrez), shellac, rosin,poloxamer, hyaluronic acid, acrylate copolymer (Eudragit L-100,L-100,55), hydroxypropyl methyl cellulose (HPMC), hydroxypropylcellulose (HPC), polyacrylic acid, polyethylene glycol, ethyl celluloseor a mixture thereof, but not limited thereto. Preferably, it may behydroxypropyl methyl cellulose (HPMC) or ethyl cellulose or a mixturethereof. Such polymer can be used by dissolving thereof in water or asolvent (for example, ethanol), but crosslinked polymers also can beused. For example, the polymer may be crosslinked polyacrylic acid, orcrosslinked polyvinyl pyrrolidone, and such crosslinked polymer can beused alone or in combination with a non-crosslinked polymer. In the caseof a polymer obtained by cross-linking polymers having excellentadhesive force to teeth or gums, it is advantageous to improve adhesionof the composition as well as to improve the residuality because it isnot dissolved in water or ethanol while exhibiting adhesive force afterabsorbing water.

The phase transition auxiliary material is a substance that can inducephase transition, control phase transition rate and adjust a degree ofphase transition, and a calcium ion can be used. It is preferable thatthe calcium ion is water-soluble, but a calcium ion, which is insolublein neutral or alkaline condition but can easily be converted intowater-soluble in an acidic condition, also can be used. For example, thephase transition auxiliary material may be at least one selected from: acalcium ion source of calcium carbonate, calcium phosphate dibasic(CaHPO₄), barium carbonate, zinc carbonate, calcium chloride, calciumlactate, calcium citrate, calcium aspartate, calcium saccharate, calciumoxovalerate, calcium gluconate, calcium lactobionate and calciumlactogluconate; a chelating agent such as barium carbonate, zinccarbonate, sodium bicarbonate, sodium carbonate, tetraborate,tripolyphosphate, ethylenediamine tetraacetic acid, tetrasodiumpyrophosphate, sodium acid pyrophosphate, Sporix (acidic sodiummetaphosphate), trisodium trimetaphosphate and the like; acetic acid,malic acid, lactic acid, gluconic acid, ascorbic acid, boric acid or amixture thereof, or a salt thereof; and NaOH, KOH or a mixture thereof.

The phase transition material, the phase transition auxiliary materialand the attachment-enhancing material of the phase transition materialcontained in the composition are exemplarily listed, but not necessarilylimited the above examples. According to another embodiment of thepresent invention, depending on the mechanism, the phase transitionmaterial, the phase transition auxiliary material and theattachment-enhancing material can be used indiscriminately. For example,if the phase transition material is polyvinyl alcohol, the phasetransition auxiliary material may be tetraborate, and the material forenhancing adhesive force may be alginate or colloidal silica. In anotherembodiment, if the phase transition material is alginate, the phasetransition auxiliary material may be calcium, and the material forenhancing adhesive force may be methyl vinyl ether and maleic acidcopolymer (gantrez).

The material for helping drug release may be any material that can forma channel, a porous structure or bubble (foam) in the formulation. Forexample, in the case that the preparation is consisting of twoformulations of the first formulation and the second formulation, oneformulation contains an acid and the other contains a base, so thatbubbles are formed in the formulation when the two formulations meet toform a viscous malleable composition. Namely, the first formulationcontains acetic acid, lactic acid, malic acid, gluconic acid, ascorbicacid and the like or a water-soluble salt thereof, e.g., sodium citrate,and the second formulation contains at least one base selected from thegroup consisting of sodium hydroxide (NaOH), potassium hydroxide (KOH),sodium bicarbonate (baking soda) and sodium carbonate. Preferably, theacid may be acetic acid, and the base may be sodium carbonate, and morepreferably, those may be sodium citrate and sodium bicarbonate, whichare an acid and a base mainly used in a toothpaste.

The active ingredient may include, for example, ingredients that canimprove oral symptoms, and for example, it may be an ingredient fortooth whitening, an ingredient for preventing cavity containing afluoride ion source, an ingredient for inhibiting tartar formation, ananti-inflammatory ingredient, an anti-bacterial ingredient, othervitamins, mineral ingredients and the like. Further, it may also includeingredients for improving sensitive teeth and for relieving itssymptoms, and the like. More specifically, for example, it may include:at least one fluoride ion source selected from the group consisting ofsodium fluoride, stannous fluoride, indium fluoride, amine fluoride andsodium monofluorophosphate; a reminerlaization agent containinghydroxyapatite; and an ingredient for tooth whitening selected fromhydrogen peroxide, carbamide peroxide, calcium peroxide, perborate,percarbonate, peroxyacid, persulfate, calcium chloride, barium chloride,magnesium chloride, lithium chloride, sodium chloride or a mixturethereof. For enhancing whitening effect, a condensed phosphate can beused together with peroxides. The condensed phosphate, which can beused, may be at least one of tetrasodium pyrophosphate (TSPP), sodiumacid pyrophosphate (SAPP), sodium tripolyphosphate (STP), sodiumpotassium pyrophosphate, tetrapotassium pyrophosphate, acidic sodiummetaphosphate and acidic sodium polyphosphate, and it may be usedtogether with peroxides. Such condensed phosphate also can be used forremoving tartar or inhibiting tartar formation. Further, it can alsocontribute to the improvement of whitening effect by removing the metalwhich affects the stain formation of teeth as a chelating agent. Theactive ingredient may include an anti-bacterial agent includingtriclosan, chlorhexidine, alexidine, hexetidine, sanguinarine,benzalkonium chloride, salicylanilide, domiphen bromide, cetylpyridiniumchloride (CPC), tetradecylpyridinium chloride (TPC) or a mixturethereof; an anti-inflammatory agent including aspirin, ketorolac,flurbiprofen, piroxicam, meclofenamic acid or a mixture thereof;thiamine, riboflavin, nicotinic acid, pantothenic acid, pyridoxine,biotin, folic acid, vitamin B12, lipoic acid, ascorbic acid, vitamin A,vitamin D, vitamin E, vitamin K or a mixture thereof; or a mixturethereof, but not limited thereto. Further, the drug effective forpreventing and improving periodontal diseases may be titrated extract ofZea Mays L. unsaponifiable fraction, Magnoliae Cortex, Myrrha, Rhatany,Chamomile, policresulen, titrated extract of Centella Asiatica, nutmegextract, dexpanthenol, β-sitosterol, acetyl salicylic acid and the likealone, or a mixture thereof at a certain mixing ratio. The ingredientfor improving and relieving sensitive teeth symptoms may be zincchloride, potassium phosphate, potassium diphosphate, calcium chloride,oxalic acid, potassium oxalate, ferric oxalate, vitamin E and the likealone, or a combination of two or more thereof.

According to one embodiment of the present invention, the preparationmay be one-formulation type, or two-formulation type consisting of thefirst formulation and the second formulation, and three or moreformulations may be mixed as required.

The first formulation and the second formulation of the two-formulationtype preparation are mixed and applied to teeth or tooth peripheries,and in order to apply the preparation to teeth or tooth peripheries, theviscosity of the preparation measured after mixing the first formulationand the second formulation may be increased, compared to before mixing,it may have moldability like dough after mixing, and may havemalleability.

The two-formulation type preparation may contain the active ingredientin the first formulation, the second formulation or both of the firstformulation and the second formulation.

The two-formulation type preparation may selectively contain the phasetransition material, the phase transition auxiliary material and theattachment-enhancing material in the first formulation, the secondformulation or both of the first formulation and the second formulation.

For example, the two-formulation type preparation may contain magnesiumalginate as a phase transition material in the first formulation. Thetwo-formulation type preparation may contain calcium chloride as amaterial for helping hardening of the phase transition material, andhydroxypropyl cellulose as a material for helping attachment to teeth ortooth peripheries in the second formulation. In this case, the activeingredient may be appropriately contained in consideration ofcompatibility of the polymers contained in the first formulation and thesecond formulation, characteristics thereof and the like.

Physical properties such as hardness, compressibility and the like ofthe preparation of the present invention may be maintained the same fromright after attachment to just before removal, and depending on thepurpose, the physical properties may be maintained the same until thesufficient amount of drug is released in the oral cavity, but at thetime of removal, hardness may be somewhat increased to fix the shape.The time of removal of the preparation of the present invention may varydepending on ingredients contained in the preparation, but it may meanat 30 min after application to teeth or tooth peripheries.

In another embodiment, the time of removal after attachment to teeth maybe, for example, the time at which drug release rate into the oralcavity becomes 60 wt % or more, preferably 65 wt % or more, morepreferably 70 wt % or more, based on the amount of the drug contained inthe preparation at the beginning.

The preparation may further comprise a backing layer as required when itis attached to teeth or tooth peripheries. The backing layer may includea water-insoluble polymer, generally used in an oral film, and forexample, polyethylene (PE), polypropylene (PP), ethylene vinyl acetate(EVA), cellulose acetate phthalate, shellac, polyvinyl acetate, ethylcellulose, polymethyl methacrylate, methacryloylethylbetain/methacrylate copolymer (Yukaformer; Manufacturer: Mitsubishi),methacrylic acid copolymer (Eudragit L 100, Eudragit L 12,5, Eudragit L100-55, Eudragit L 30D-55), aminoalkyl methacrylate copolymer (EudragitE 100, Eudragit E 12,5, Eudragit RL 100, Eudragit RL 30D) and the likemay be used.

In one embodiment of the present invention, the preparation can beeasily removed at the time of removal after drug release by toothbrushing, and the time of removal may be at the time after 30 min afterattachment.

Advantageous Effects

The preparation of the present invention can give high adhesive force tothe desired site despite gaps between teeth or curves of teeth.

The preparation is adhered well to gaps between teeth, thereby havingexcellent drug delivery efficiency. Further, it is possible tosufficiently secure the contact time between the drug delivery site andthe preparation of the present invention because the preparation doesnot flow down or is not diluted with saliva after attachment, andtherefore, it is advantageous to achieve the desired efficacy.

Further, the preparation can be used conveniently because it does notflow down when applied to teeth.

BRIEF DESCRIPTION OF THE DRAWINGS

Other objects and aspects of the present invention will become apparentfrom the following descriptions of the embodiments with reference to theaccompanying drawings in which:

The accompanying drawings illustrate a preferred embodiment of thepresent invention and together with the foregoing disclosure, serve toprovide further understanding of the technical spirit of the presentinvention, and thus, the present invention is not construed as beinglimited to the drawing.

In the drawing, T refers to teeth, and 1 refers to the conventionalstrip for attaching to teeth. 2 refers to an active ingredient, and 10refers to the oral preparation manufactured according to one embodimentof the present invention.

FIG. 1 is a drawing showing (a) the conventional strip for attaching tothe oral cavity and (b) the preparation according to one embodiment ofthe present invention. Unlike the conventional strip wherein an activeingredient 2 and a strip 1 are in separate layers, the preparationaccording to one embodiment of the present invention can have the formthat the drug is dispersed in the preparation.

FIG. 2 is a drawing prefiguratively showing the process of attaching thepreparation of the present invention 10 to teeth T and then removing thepreparation from the teeth over time.

FIG. 3 is a drawing prefiguratively showing the process of hardening thepreparation according to one embodiment of the present invention afterapplying and adhering the preparation to teeth. As can be seen from FIG.3, the preparation of the present invention can reach gaps betweenteeth.

FIG. 4 is a drawing prefiguratively showing the process of attaching thepreparation 10 to teeth T and then removing the preparation from theteeth over time according to another embodiment of the presentinvention.

EXAMPLES

Hereinafter, the present invention will be described in more detailthrough the following embodiments. However, the embodiments according tothe present invention may be modified in many different forms, and thescope of the present invention shall not be construed as being limitedto the embodiments described below. The embodiments of the presentinvention are provided for illustration to help a full understanding ofthe present invention. Unless stated otherwise, % used herein areunderstood to mean wt %.

Preparation and Test of Oral Composition in a Hardening Ointment-Phase

[Preparation of Oral Preparation]

Oral preparations of Examples and Comparative Examples having thefollowing composition were prepared or purchased.

Preparations of Examples 1 to 3 were manufactured according to thefollowing method. The powder preparation of Example was mixed by using apowder mixer, the gel of Example was prepared by mixing a polymer with amechanical mixer at a constant rate without aggregation. Further,Example 3 was prepared by mixing with a mechanical mixer after adjustingtemperature to 50° C.

TABLE 1 Example 3 Example 2 (Gel type, which is Phase Example 1 (Filmcoating (Dual paint type with applicator transition type type withseparate backing layer) (dual syringe + mixing tip)) by saliva) FirstAlginate 12% First Alginate 3.8% GMO 48.0% formulation Calcium Sulfate15% formulation Acetic Acid 2.5% EC 8.0% (powder) Sodium Phosphate 2%(gel-like) Magnoliae Cortex 0.1% Hydrogen Peroxide 6% Diatomite to 100%(active ingredient) (active ingredient) Second Gantrez 0.38% Water to100% Ethanol 44.0% formulation Zinc Chloride 0.18% Second Alginate 3.8%(liquid-like (active ingredient) formulation Calcium Carbonate 2.0%viscosity) Water to 100% (gel-like) Sodium Carbonate 1.9% Backing layerPE film Water to 100%

Comparative Examples 1 to 5 were prepared. Comparative Example 1 usedP&G SensiStop (containing active ingredient of improving sensitiveteeth) and Comparative Example 2 used Parodontax (containing activeingredient of improving gingivitis).

Comparative Example 3 used Alginate Gel prescription (alginatewater-soluble gel prescription, tooth whitening), Comparative Example 4used Poloxamer prescription as a Temperature Sensitive Polymer (toothwhitening) and Comparative Example 5 used dental impression materialprescription (silicone dual-syringe prescription).

TABLE 2 Comparative Example 5 Dental impression material ComparativeExample 2 (Selection VPS Putty) (Product name: Formulation: ComparativeExample 1 Parodontax ™) Comparative Example 3 Comparative Example 4Reactive silicone gel (P&G SensiStop ™) Formulation: (Alginate Gel)(Poloxamer) (First formulation, Formulation: Strip ToothpasteFormulation: Gel Formulation: Liquid Second formulation) Water Myrrhatint Alginate 1.5% PluronicF127 20% Vinyl Polysiloxane Glycerin Rhatanytint Hydrogen Peroxide 6% Carbamide Peroxide 16% Impression MaterialCellulose Gum Chamomile tint Water to 100% (H₂O₂ 5.6%) (Firstformulation, Dipotassium Oxalate Water to 100% Second formulation)(active ingredient ) Carbomer Sodium Hydroxide Sodium Benzoate PotassiumSorbate PE film

[Test for Comparing Viscosity, Solubility and Convenience of Use BeforeAttachment or at the Beginning of Attachment and Just Before Removal]

Test Method

1. Viscosity comparison test (Test method: Viscosity was measured byusing Rotary Viscometer)

-   -   Evaluation device: Brookfield Viscometer, No. 6, or 7 spindle, 5        rpm to 20 rpm, 20° C. (room temperature)    -   Evaluation method: Viscosity of Comparative Example and Example        was measured by using Brookfiled Viscometer.

As follows, i) viscosity at the first application, ii) viscosity inadhesion, iii) and viscosity just before removal were measured. But, inthe case of the prescription consisting of the first formulation and thesecond formulation, each viscosity measured before mixing the firstformulation and the second formulation was referred to as the viscosityat the time of manufacture, and in the case of consisting of only thefirst formulation, the viscosity at the time of manufacture was referredto the same as the viscosity before the first application.

i) Viscosity at the first application: in the case of consisting of thefirst formulation and the second formulation, it is the same as theviscosity right after mixing, and in the case of consisting of only thefirst formulation, it is the same as the viscosity at the time ofmanufacture.

ii) Viscosity in adhesion: in the case of consisting of the firstformulation and the second formulation, the viscosity is increased fromthe moment of mixing, and the viscosity means the viscosity in the statewhere shape transformation can occur even at a small pressure. In thistest, for example, in the case of a preparation whose total use time is10 min, the preparation was adhered to the desired site at 5 min afterapplication, and in the case of a preparation whose total use time is 30min, the preparation was adhered to the desired site at 5 min to 10 minafter application. The viscosity at this time was measured as theviscosity in adhesion.

iii) Viscosity just before removal or upon completion of drug release(the time at which about 70% to 100% of drug is released): it means theviscosity when no further viscosity increase occurs.

For example, in the case of a prescription for tooth whitening andmaintaining the whitening effect, which consists of the firstformulation and the second formulation, and is attached for 30 min,{circle around (1)} Viscosity at the time of manufacture means eachviscosity before mixing, {circle around (2)} Viscosity at the firstapplication means the viscosity just before application to teeth (whenconsisting of the first formulation and the second formulation, it meansthe viscosity right after mixing) {circle around (3)} Viscosity inadhesion means the viscosity at 10 min after application to teeth,{circle around (4)} Viscosity just before removal or upon completion ofdrug release means the viscosity at 30 min after application to teeth.

2. Drug release rate comparison test (Test method: after releasing test,the concentration of an active ingredient in a solution was quantified)

A) Manipulation

0.9% Sodium chloride solution 500 mL is poured in a test tube and atemperature of a test solution is maintained at 32±0.5° C. during drugrelease test. Example or Comparative Example as a sample is fixed on theupper side of a disk which can be used as a sinker without absorbing,interfering or reacting so that a target attachment surface facesoutward. Then, the disk is placed in the test tube with thesample-attached side facing up, and drug release time is calculated fromthis point of time. The sample-attached disk is aligned parallel to thebottom of the test tube and a paddle blade. Distance between the paddleblade and the sample surface is set to 25±2 mm, and revolutions per min(rpm) is set to 25. At the time of sampling, 100 mL of sample solutionis collected at a fixed position (a position 1 cm away from the wall ofthe test tube, between the top of the paddle blade and the test liquidsurface) 30 min after the start of the test.

Drug analysis method: Depending on the drug or the content, anappropriate analysis is selected. For example, peroxides are analyzed bytitration, metal salts are analyzed by ICP analysis, and naturalextracts are analyzed by HPLC.

3. Solubility comparison test: In the present invention, solubility isdefined as shape retention force during artificial saliva (0.9% NaClaqueous solution) release test. Recorded through comparative observation(Whether the shape is collapsed or maintained, or the same thickness andheight are maintained or decreased in the USP drug release test wasobserved and recorded)

{circle around (1)} Solubility at the time of manufacture: in the caseof consisting of the first formulation and the second formulation, 1 geach was taken and loaded in the same manner as the drug release test,and then solubility was observed.

{circle around (2)} In the case of consisting of the first formulationand the second formulation, solubility at the first application, inadhesion and just before removal was measured by loading the drug in thesame manner as the drug release test, and observing shape transformationover time.

4. Convenience of use comparison test (Whether wet type or dry type):The characteristics of the formulation applied to the target in the oralcavity cause the inconvenience to use because the formulation is smearedto the hands while being applied. Further, those cause the inconvenienceto use because the formulation is smeared to gums or hands whileapplying and standing for a certain time and is smeared to the handduring removal. Wet type is characterized in that it is smeared to thehands when touched, and dry type is characterized in that it is notsmeared when touched by hands because it maintains its shape.

[Efficacy/Effect Comparison Test]

1. Clinical Survey Related to Improvement of Sensitive Teeth for Humans

1) Test subject and instructions: Example 1 group and ComparativeExample 1 group were attached to the sensitive teeth area for 10 minonce a day and then removed.

2) After 1 week use, the survey was conducted to 15 volunteers who feltsensitive teeth per each group using 3-point Likert scale.

3) Criteria

1 point: Compared to before use, the sensitive teeth symptoms weresimilar or worsened.

2 point: Compared to before use, the sensitive teeth symptoms wereslightly relieved.

3 point: Compared to before use, the sensitive teeth symptoms were a lotrelieved.

2. Clinical Survey Related to Improvement of Gingivitis Symptoms-Reliefof Gum Pain for Humans

1) Test subject and instructions: Example 2 group and ComparativeExample 2 group were attached to the gum pain area for 10 min once a dayand then removed.

2) After 1 week use, the survey was conducted to 15 volunteers who feltgum pain per each group using 3-point Likert scale.

3) Criteria

1 point: Compared to before use, the gum pain symptoms were similar orworsened.

2 point: Compared to before use, the gum pain symptoms were slightlyrelieved.

3 point: Compared to before use, the gum pain symptoms were a lotrelieved.

3. Evaluation of Whitening Effect by In Vitro Tooth Whitening EvaluationMethod Using Artificial Teeth

(1) Preparation and Coloring of Hydroxyapatite (HAP) Tablet Sample

Artificial teeth were made by using hydroxyapatite, a component thatforms 96% or more of teeth. Namely, hydroxyapatite powder was tabletedwith IR press or tablet machine and then sintered at 1000° C. Accordingto Stookey method, a process of impregnating a sample in TSB (trypticasesoybroth) solution in which tea, coffee, iron and mucin protein weredissolved and drying thereof was repeated for 1 week to prepare acolored artificial sample. The colored sample was washed lightly withrunning water using a toothbrush to remove stains that could be easilydissolved or easily removed by water, and then dried. The initial L(lightness) value was measured with a chroma meter.

(2) In Vitro Tooth Whitening Evaluation Method Using Colored ArtificialTeeth

After attaching Example 3, Comparative Example 3 and Comparative Example4 to a colored artificial teeth, respectively, the artificial teeth wasallowed to stand for 30 min under conditions of the oral cavity, i.e.,37° C., 98% humidity. The sample was washed with water after removingExample and Comparative Example and then dried. Then, L value wasmeasured. The delta L value, which is the difference between the Lvalues before and after attachment, was calculated.

[Test for Comparing Viscosity and Solubility Before Attachment or at theBeginning of Attachment and Just Before Removal]

1. Viscosity of Example and Comparative Example at Each Stage

(At this time, viscosity at each stage may have an error range of about+/−50 cPs.)

TABLE 3 Comparative Comparative Comparative Example 1 Example 2 Example3 Example 3 Example 4 Example 5 At the time of Second First formulation1,150 cps 13,000 cps 400 cps First formulation manufacture formulation(14,000 cps) (700,000 cps) (5 cps) Second Second formulation formulation(14,000 cps) (700,000 cps) First application 30,000 cps 20,000 cps 1200cps 13,000 cps 400 cps 700,000 cps In adhesion 120,000 cps 50,000 cps2500 cps* 13,000 cps 600 cps >2,000,000 cps Just before 180,000cps >50,000 cps >5000 cps* 13,000 cps 600 cps Not measurable removal(Upon completion of drug release)

As listed in Table 3, it was confirmed that after the first applicationof the preparation, the viscosity of the preparations of Examples of thepresent invention was increased until adhesion of the preparations.

2. Drug Release Rate of Example and Comparative Example at Each Stage

TABLE 4 Comparative Example 1 Example 3 Example 5 After 10 min from  50%   60%   5% attachment After 30 min from >70% >80% <5% attachment

As can be seen from Table 4, when the total loaded amount of drug isreferred as 100, it can be found that 70% or more of the drug wasreleased at the time of removal of the preparation, which was 30 minafter attachment. However, in the case of Comparative Example 5corresponding to a dental impression material, it can be found thatincrease of the viscosity over time is the same as the preparation ofthe present invention showed, but drug release was not smooth.

3. Solubility/Shape Retention Force of Preparation of Example andComparative Example at Each Stage

TABLE 5 Comparative Comparative Comparative Example 1 Example 2 Example3 Example 4 Example 5 Solubility at Second formulation First formulationDissolved Dissolved First formulation the time of (Dissolved)(Dissolved) (Maintained shape 100%) manufacture Second formulationSecond formulation (Dissolved) (Maintained shape 100%) SolubilityMaintained shape Maintained shape Dissolved Partly maintained Maintainedshape (100%) at first (100%) (>90%) shape (>50%) application PreparationMaintained shape Maintained shape Dissolved Partly maintained Maintainedshape (100%) residue (100%) (>90%) shape (<50%) just before removal

As can be seen from Table 5, it can be found that the preparations ofthe present invention have excellent shape retention force just beforeremoval. Namely, from the above results, it can be found that thepreparations of the present invention can be adhered to fit to gapsbetween teeth after application, and its shape can be maintained justbefore removal.

4. Comparison of Convenience of Use of Example and Comparative Example

TABLE 6 Comparative Comparative Comparative Example 1 Example 2 Example1 Example 2 Example 4 Degree of smear Second formulation Firstformulation Smeared Smeared Smeared at the time of (Smeared: Wet type)(Smeared: Wet type) (Wet type) (Wet type) (Wet type) manufacture Secondformulation (Smeared: Wet type) Degree of smear Almost not smearedAlmost not smeared Smeared Smeared Smeared at first (Like dry type)(Like dry type) (Wet type) (Wet type) (Wet type) application Degree ofsmear Not smeared Not smeared Smeared Smeared Smeared just before (Wettype) (Wet type) (Wet type) removal

Table 6 shows the result of confirming convenience of use in the courseof applying the preparations of the present invention. As can be seenfrom the above result, it was confirmed that the preparations of thepresent invention can be used conveniently and sanitarily because thedrug was almost not smeared to the hands when applied and adhered toteeth, and there is no unnecessary loss of the drug. However, thepreparations of Comparative Examples gave loss of the drug orinconvenience because the drug was smeared to the hands.

5. Comparison of Efficacy of Example and Comparative Example

TABLE 7 Comparative Comparative Example 1 Example 1 Example 2 Example 2Survey score 2.7 1.5 for sensitive teeth symptom Survey score 2.4 1.4for gum pain

As can be seen from Table 7, it was confirmed that Example 1 had bettereffect of relieving sensitive teeth, compared to Comparative Example 1,and it was confirmed that Example 2 had better effect of relieving gumpain symptoms, compared to Comparative Example 2.

These results suggest that the formulations of Examples of the presentinvention have excellent degree of adhesion to teeth and gaps betweenteeth, so that active ingredient s are effectively delivered to thetarget site.

Further, because Comparative Examples 1 and 2 are toothpaste-type andthe holding time of the drug delivered at the time of the firstapplication (brushing) was not long, the active ingredient graduallydisappeared over time. However, in the case of the preparation ofExamples of the present invention providing the time for stablepenetration of the active ingredient for a certain period of time, itwas thought that loss rate of the active ingredient was low.

TABLE 8 ΔL(Use once) ΔL(Use twice) Example 3 16.54 ± 2.19  31.49 ± 3.05 Comparative Example 3 5.29 ± 1.54 9.89 ± 1.85 Comparative Example 4 7.82± 3.19 13.26 ± 1.99 

As can be seen from Table 8, Example 3 showed better tooth whiteningeffect, compared to Comparative Examples 3 and 4. It was confirmed thatin the case of Comparative Examples 3 and 4, which are gel-type andliquid-type, respectively, the amount of the active ingredient deliveredto teeth was smaller than the loaded amount, and the whitening effectwas significantly low because the amount that flows down or disappearswithout being fixed after being applied to teeth was a lot.

Preparation and Test of Oral Preparation Having Malleability

Additional oral preparations, including Examples and ComparativeExamples having the same composition as some of Examples 1 to 3 andComparative Examples, were prepared and the following tests wereconducted.

[Preparation of Oral Preparation]

TABLE 9 Example 3 Example 4 Example 1 Example 2 (Gel type, which is(Compression band type, (Film coating type (Dual paint type withapplicator Phase transition type Example having form like with separatebacking layer) (dual syringe +mixing tip)) by saliva) plaster) FirstAlginate 12% First Alginate 3.8% First formulation: First formulation(Liquid): formulation Calcium Sulfate 15% formulation Acetic Acid 2.5%Gel-like PVA 3% (powder) Sodium Phosphate 2% (gel-like) Magnoliae Cortexextract Second formulation: Magnoliae Cortex extract Diatomite to 100%0.1% (active ingredient) GMO 48.0% 0.1% Water to 100% EC 8.0% Ethanol 1%Hydrogen Peroxide 6% Water to 100% Second Gantrez 0.38% Second Alginate3.8% (active ingredient) Second formulation formulation Zinc Chloride0.18% formulation Calcium Carbonate 2.0% Ethanol 44.0% (Liquid):(liquid-like (active ingredient) (gel-like) Sodium Carbonate 1.9% Borax4% viscosity) Water to 100% Water to 100% Backing PE film layer

Comparative Examples 1 to 3 and 5 were prepared as follows.

TABLE 10 Comparative Example 5 Dental impression material ComparativeExample 2 (Selection VPS Putty) (Product name: Reactive silicone gelComparative Example 1 Parodontax ™) Comparative Example 3 (Formulation:(P&G SensiStop ™) Formulation: (Alginate Gel) First formulation,Formulation: Strip Toothpaste Formulation: Gel Second formulation) WaterMyrrha tint Alginate 1.5% Vinyl Polysiloxane Glycerin Rhatany tintHydrogen Peroxide 6% Impression Material Cellulose Gum Chamomile tintWater to 100% (First formulation, Dipotassium Oxalate Secondformulation) (active ingredient) Carbomer Sodium Hydroxide SodiumBenzoate Potassium Sorbate PE film

Comparative Example 1 used P&G SensiStop (containing active ingredientof improving sensitive teeth) and Comparative Example 2 used Parodontax(containing active ingredient of improving gingivitis). ComparativeExample 3 used PVA Gel prescription (Water-soluble gel prescription,improving gingivitis/periodontitis) and Comparative Example 5 useddental impression material prescription (silicone dual-syringeprescription).

[Tests for Comparing Viscosity, Solubility and Convenience of Use BeforeAttachment or at the Beginning of Attachment and Just Before Removal]

Test Method

1. Hardness Comparison Test (Test Method: Measured by Using TextureAnalyzer)

-   -   Evaluation device: Stable Micro System TA XT Plus    -   Evaluation method: Hardness of Comparative Example and Example        was measured by using Texture Analyzer.

Hardness was measured at compression test mode of TA (Texture Analyzer).After filling Example and Comparative Example into a 50 mL beaker, a 20mm diameter aluminum probe for hardness measurement was set, and thenhardness was measured with test speed of 1.5 mm/s, distance as targetmode and distance of 10 mm. The hardness calculated from the device isthe peak value of the first cycle.

{circle around (1)} Hardness at the time of manufacture: In the case ofprescription consisting of the first formulation and the secondformulation, each hardness measured before mixing the first formulationand the second formulation. In the case of consisting of only the firstformulation, the hardness at the time of manufacture was referred to thesame as the hardness before the first application.

{circle around (2)} Hardness at the first application: In the case ofprescription consisting of the first formulation and the secondformulation, hardness right after mixing. In the case of consisting ofonly the first formulation, the hardness was referred to the same as thehardness at the time of manufacture.

{circle around (3)} Hardness in adhesion: In the case of consisting ofthe first formulation and the second formulation, hardness is increasedfrom the moment of mixing, and the hardness means the hardness in thestate where shape transformation can occur even at a small pressure(Hardness when adhered to the desired site)

{circle around (4)} Hardness just before removal or upon completion ofdrug release: Hardness when no further hardness increase occurs.Hardness just before removal. Hardness when drug release is completed.

For example, in the case of a prescription for treating and preventinggingivitis, which consists of the first formulation and the secondformulation, and is attached for 30 min, {circle around (1)} Hardness atthe time of manufacture means each hardness before mixing, {circlearound (2)} Hardness at the first application means the hardness justbefore application to teeth (when consisting of the first formulationand the second formulation, it means the hardness right after mixing){circle around (3)} Hardness in adhesion means the hardness at 10 minafter application to teeth, {circle around (4)} Hardness just beforeremoval or upon completion of drug release means the hardness at 30 minafter application to teeth.

2. Compressibility Comparison Test (Test Method: Measured by UsingTexture Analyzer)

Evaluation device: Stable Micro System TA XT Plus

Evaluation method: compressibility of Comparative Example and Examplewas measured by using Texture Analyzer.

Compressibility was measured at compression test mode of TA (TextureAnalyzer). After filling Example and Comparative Example into a 50 mLbeaker, a 20 mm diameter aluminum probe for compressibility measurementwas set, and then compressibility was measured with test speed of 1.5mm/s, distance as target mode and distance of 10 mm. The compressibilitycalculated from the device is the area value of the first cycle.

3. Malleability Comparison Test (Test Method: Degree of Stretch whenPressing with a Constant Force after Measuring the Initial Length)

In the case of a sample transformable on a PET film, 1 g each of thesample was made to have the same length and breadth (1 cm²), a PE filmwas placed thereon, and then a 1 cm² grid plate was to show the PE filmbelow. Then, when pressing the sample with a constant force (2 kgf/cm²),the degree of stretch in length was measured using a 1 cm² grid plate,and elongation percentage was calculated by calculating the averagedegree of elongation in all directions. The elongation percentage wasmeasured under a general laboratory condition, i.e., under a conditionof relative humidity of about 65%, 25° C.

4. Drug Release Rate Comparison Test (Test Method: After Releasing Test,the Concentration of an Active Ingredient in a Solution was Quantified)

A) Manipulation

0.9% Sodium chloride solution 500 mL is poured in a test tube and atemperature of a test solution is maintained at 32±0.5° C. during drugrelease test. Example or Comparative Example as a sample is fixed on theupper side of a disk which can be used as a sinker without absorbing,interfering or reacting so that a target attachment surface facesoutward. Then, the disk is placed in the test tube with thesample-attached side facing up, and drug release time is calculated fromthis point of time. The sample-attached disk is aligned parallel to thebottom of the test tube and a paddle blade. Distance between the paddleblade and the sample surface is set to 25±2 mm, and revolutions per min(rpm) is set to 25. At the time of sampling, 100 mL of sample solutionis collected at a fixed position (a position 1 cm away from the wall ofthe test tube, between the top of the paddle blade and the test liquidsurface) 30 min after the start of the test.

B) Drug Analysis Method

Depending on the drug or the content, an appropriate analysis isselected. For example, peroxides are analyzed by titration, metal saltsare analyzed by ICP analysis, and natural extracts are analyzed by HPLC.

5. Convenience of Use Comparison Test (Adhesive Force, Shape RetentionForce, Adhesive Force, Removability and the Like)

The characteristics of the formulation applied to the target in the oralcavity cause the inconvenience to use because the formulation is smearedto the hands while being applied. Further, those cause the inconvenienceto use because the formulation is smeared to gums or hands whileapplying and standing for a certain time and is smeared to the handduring removal. Wet type is characterized in that it is smeared to thehands when touched, and dry type is characterized in that it is notsmeared when touched by hands because it maintains its shape.

[Efficacy/Effect Comparison Test]

1. Clinical Survey Related to Improvement of Sensitive Teeth for Humans

1) Test subject and instructions: Example 2 group and ComparativeExample 1 group were attached to the sensitive teeth area for 10 minonce a day and then removed.

2) After 1 week use, the survey was conducted to 15 volunteers who feltsensitive teeth per each group using 3-point Likert scale.

3) Criteria

1 point: Compared to before use, the sensitive teeth symptoms weresimilar or worsened.

2 point: Compared to before use, the sensitive teeth symptoms wereslightly relieved.

3 point: Compared to before use, the sensitive teeth symptoms were a lotrelieved.

2. Clinical Survey Related to Improvement of Gingivitis Symptoms-Reliefof Gum Pain for Humans

1) Test subject and instructions: Examples 1 and groups and ComparativeExample 2 group were attached to the gum pain area for 10 min once a dayand then removed.

2) After 1 week use, the survey was conducted to 15 volunteers who feltgum pain per each group using 3-point Likert scale.

3) Criteria

1 point: Compared to before use, the gum pain symptoms were similar orworsened.

2 point: Compared to before use, the gum pain symptoms were slightlyrelieved.

3 point: Compared to before use, the gum pain symptoms were a lotrelieved.

3. Evaluation of Whitening Effect by In Vitro Tooth Whitening EvaluationMethod Using Artificial Teeth

(1) Preparation and Coloring of Hydroxyapatite (HAP) Tablet Sample

Artificial teeth were made by using hydroxyapatite, a component thatforms 96% or more of teeth. Namely, hydroxyapatite powder was tabletedwith IR press or tablet machine and then sintered at 1000° C. Accordingto Stookey method, a process of impregnating a sample in TSB (trypticasesoybroth) solution in which tea, coffee, iron and mucin protein weredissolved and drying thereof was repeated for 1 week to prepare acolored artificial sample. The colored sample was washed lightly withrunning water using a toothbrush to remove stains that could be easilydissolved or easily removed by water, and then dried. The initial L(lightness) value was measured with a chroma meter.

(2) In Vitro Tooth Whitening Evaluation Method Using Colored ArtificialTeeth

After attaching Example 4 and Comparative Example 3 to a coloredartificial teeth, respectively, the artificial teeth was allowed tostand for 30 min under conditions of the oral cavity, i.e., 37° C., 98%humidity. The sample was washed with water after removing Example 4 andComparative Example 3 and then dried. Then, L value was measured. Thedelta L value, which is the difference between the L values before andafter attachment, was calculated.

[Test for Comparing Hardness Before Attachment or at the Beginning ofAttachment and Just Before Removal]

1. Hardness of Example and Comparative Example at Each Stage

TABLE 11 Example Example Example Comparative Comparative 4 1 2 Example 3Example 5 At the Not Not Not Not First time of measur- measur- measur-measurable formulation manu- able able able 100 g facture Secondformulation 100 g First 150 g   180 g 120 g Not     300 g appli-measurable cation In 150 g   5580 g 450 g Not >33,600 g adhesionmeasurable Just before 150 g 12,000 g 600 g Not >>Not removal measurablemeasurable (Upon com- pletion of drug release)

As listed in Table 11, the oral preparations of Examples of the presentinvention had the hardness in adhesion of around 5,000 g or less, andthose have advantages that it can be transformed by a small force due tolow hardness, and therefore, when pressed lightly with a finger at thebeginning, it can be stretched to the desired length, and thepreparation has little feeling of foreign body in gums or oral cavitybecause the preparation is soft. On the contrary, in the case ofComparative Example 3, there is no hardness, so it is equivalent toExamples in terms of softness. However, it has disadvantages that it isdifficult to maintain shape after application because it is a generalliquid gel, it is scattered by pressing with a finger, it isinconvenient to use because it is smeared to the hands and easilysmeared to the contact site to the gums, and it is easily washed out inthe humid oral cavity. In the case of Comparative Example 5, there ishigh hardness. Thus, it has disadvantages that it may give a burden tosoft gums because it is impossible to transform shape if it is notquickly adhered after application due to its hardness, and it isimpossible to release a drug after the hardness is increased.

2. Compressibility of Example and Comparative Example at Each Stage

TABLE 12 Example Example Example Comparative Comparative 4 1 2 Example 3Example 5 At the Not Not Not Not First time of measur- measur- measur-measurable formulation manu- able able able 100 gs facture Secondformulation 100 gs First 700 gs   680 gs  650 gs Not     1200 gs appli-measurable cation In 700 gs 11,000 gs 1500 gs Not >55,000 gs adhesionmeasurable Just before 700 gs 16,000 gs 2000 gs Not >>Not removalmeasurable measurable (Upon com- pletion of drug release)

As listed in Table 12, the oral preparations of Examples of the presentinvention have low compressibility in adhesion, and it means that thosedo not take much effort to make the desired transformation for a certainperiod of time. Those have an advantage that when pressed lightly with afinger, desired deformations can be obtained, including not only sizedeformation but also shape deformation, which makes it possible toeasily fill teeth gaps in many teeth simultaneously even if the teethare uneven. On the contrary, in the case of Comparative Example 3, ithas disadvantages that it is difficult to maintain shape afterapplication because it is a general liquid gel without hardness, it isscattered by pressing with a finger, it is inconvenient to use becauseit is smeared to the hands and easily smeared to the contact site to thegums, and it is easily washed out in the humid oral cavity. In the caseof Comparative Example 5, compressibility is sharply increased withinseveral min after application and the value is too high. Thus, it hasdisadvantages that it is hard to use because it is impossible totransform shape if it is not quickly adhered after application due toits hardness, and it is difficult to release a drug.

3. Comparison of Malleability of Example and Comparative Example

TABLE 13 Comparative Comparative Example 4 Example 1 Example 3 Example 5At first >300% >150% Not maintained 150% application shape (Within 2min) In adhesion >300% >150% Not maintained Fixed (Within 10 shape min)Just before >300%   150% Not maintained Fixed removal shape (after 30min)

As can be seen from Table 13, the preparations of the present inventioncould maintain the malleability just before removal. By suchmalleability, the preparations of the present invention could becompletely adhered to gap between teeth, and effectively deliver thedrug to gaps between teeth and gums.

4. Drug Release Rate of Example and Comparative Example

TABLE 14 Comparative Example 1 Example 2 Example 3 After 10 min from  50%   60%   5% attachment After 30 min from >70% >80% <5% attachment

As can be seen from Table 14, in the case of Examples, it can beconfirmed that 70% or more of the drug was released at the time ofremoval of the preparation, which was 30 min after attachment, based onthe loaded amount of the drug. However, in the case of ComparativeExample, it can be confirmed that removal of the preparation increasedthe hardness and limited the drug release.

5. Comparison of Convenience of Use of Example and Comparative Example

TABLE 15 Comparative Comparative Comparative Example 4 Example 1 Example1 Example 2 Example 3 Degree of smear at First formulation Firstformulation Smeared Smeared Smeared the time of (Smeared: Wet type)(Smeared: Powder type) (Wet type) (Wet type) (Wet type) manufactureSecond formulation Second formulation (Smeared: Wet type) (Smeared: Wettype) Degree of smear at Not smeared Almost not smeared Smeared SmearedSmeared first application (Dry type) (Like dry type) (Wet type) (Wettype) (Wet type) Degree of smear just Not smeared Not smeared SmearedSmeared Smeared before removal (Dry type) (Wet type) (Wet type) (Wettype)

As cab be seen from Table 15, in the case of Comparative Examples of thepresent invention, the drug was smeared to the hands in the course ofapplying the preparations on the surface of teeth, but Examples of thepresent invention could be conveniently used because the drug was almostnot smeared to the hands.

Comparative Comparative Example 4 Example 1 Example 1 Example 2 Surveyscore for — 2.7 1.5 — sensitive teeth Survey score for gum pain 2.4 — —1.4

As can be seen from Table 16, it was confirmed that Example 1 had bettereffect of relieving sensitive teeth, compared to Comparative Example 1,and it was confirmed that Example 4 had better effect of relieving gumpain symptoms, compared to Comparative Example 2.

These results suggest that the formulations of Examples of the presentinvention have excellent degree of adhesion to teeth and gaps betweenteeth, so that active ingredient s are effectively delivered to thetarget site.

Further, because Comparative Examples 1 and 2 are toothpaste-type andthe holding time of the drug delivered at the time of the firstapplication (brushing) was not long, the active ingredient graduallydisappeared over time. However, in the case of the preparation ofExamples of the present invention providing the time for stablepenetration of the active ingredient for a certain period of time, itwas thought that loss rate of the active ingredient was low.

TABLE 17 ΔL (Use once) ΔL (Use twice) Example 2 16.54 ± 2.19 31.49 ±3.05 Comparative Example 3  5.29 ± 1.54  9.89 ± 1.85

As can be seen from Table 17, Example 2 showed better tooth whiteningeffect, compared to Comparative Example 3. It was confirmed that in thecase of Comparative Example 3, which is gel-type, the amount of theactive ingredient delivered to teeth was smaller than the loaded amount,and the whitening effect was significantly low because the amount thatflows down or disappears by force without being fixed after beingapplied to teeth was a lot.

INDUSTRIAL APPLICABILITY

The preparation of the present invention can be well adhered to gapsbetween teeth well, and therefore, it can effectively deliver a drug toteeth of gaps between teeth. The present invention can provide apreparation attachable in the oral cavity, which is convenient to usebecause it does not flow down when applied to teeth.

The present invention has been described in detail. However, it shouldbe understood that the detailed description and specific examples, whileindicating preferred embodiments of the disclosure, are given by way ofillustration only, since various changes and modifications within thescope of the disclosure will become apparent to those skilled in the artfrom this detailed description.

1. A preparation for attaching to teeth or tooth peripheries, whichcomprises: an oral composition in a hardening ointment-phase; and anactive ingredient for intra-oral delivery, wherein the oral compositionin the hardening ointment-phase comprises a phase transition material, aphase transition auxiliary material, and an attachment-enhancingmaterial of a phase transition composition, wherein the phase transitionmaterial includes carrageenan, pectin, xyloglucan, gellan gum, ammoniumalginate, magnesium alginate, potassium alginate, sodium alginate,lithium alginate, chitosan, poly-lactic acid (poly(D,L-lactic acid)),polylactide-co-glycolide (poly(DL-lactide-co-glycolide)),poly-caprolactone, polyacrylic acid (carbopol), polyvinylacetal diethylaminoacetate (AEA), hydroxypropylmethyl cellulose, poly(methacrylicacid)-poly(ethylene glycol), poly(D,L-lactide)-block-poly(ethyleneglycol)-block-poly(D,L-lactide), PEG-oligoglycolyl-acrylate,poly(N-isopropyl acrylamide), sucrose acetate isobutyrate, polyvinylalcohol, glyceryl monooleate, glyceryl monolinoleate, glycerylmonoarachidonate, glyceryl monostearate, or a mixture thereof, whereinthe phase transition auxiliary material includes a calcium ion source ofcalcium sulfate, calcium carbonate, calcium phosphate dibasic (CaHPO₄),barium carbonate, zinc carbonate, calcium chloride, calcium lactate,calcium citrate, calcium aspartate, calcium saccharate, calciumoxovalerate, calcium gluconate, calcium lactobionate or calciumlactogluconate; a chelating agent of barium carbonate, zinc carbonate,sodium bicarbonate, sodium carbonate, tetraborate or tripolyphosphate;acetic acid, malic acid, lactic acid, gluconic acid, ascorbic acid,boric acid or a mixture or a salt thereof; or NaOH, KOH or a mixturethereof, wherein the attachment-enhancing material of the phasetransition composition includes precipitated silica for thickening,colloidal silicone dioxide, polyvinyl pyrrolidone, poly methyl vinylether and maleic acid copolymer, shellac, rosin, poloxamer, hyaluronicacid, acrylate copolymer, hydroxypropyl methyl cellulose (HPMC),hydroxypropyl cellulose (HPC), polyacrylic acid, polyethylene glycol,ethyl cellulose or a mixture thereof, or a crosslinked body thereof,wherein the active ingredient is sodium fluoride, stannous fluoride,indium fluoride, amine fluoride, sodium monofluorophosphate, tetrasodiumpyrophosphate (TSPP), sodium acid pyrophosphate (SAPP), sodiumtripolyphosphate (STP), sodium potassium pyrophosphate, tetrapotassiumpyrophosphate, acidic sodium metaphosphate, acidic sodium polyphosphate,triclosan, chlorhexidine, alexidine, hexetidine, sanguinarine,benzalkonium chloride, salicylanilide, domiphen bromide, cetylpyridiniumchloride (CPC), tetradecylpyridinium chloride (TPC), aspirin, ketorolac,flurbiprofen, piroxicam, meclofenamic acid, thiamine, riboflavin,nicotinic acid, pantothenic acid, pyridoxine, biotin, folic acid,vitamin B12, lipoic acid, ascorbic acid, vitamin A, vitamin D, vitaminE, vitamin K, titrated extract of Zea Mays L. unsaponifiable fraction,Magnoliae Cortex, Myrrha, Rhatany, Chamomile, policresulen, titratedextract of Centella Asiatica, nutmeg extract, dexpanthenol,β-sitosterol, acetyl salicylic acid, zinc chloride, potassium phosphate,potassium diphosphate, calcium chloride, oxalic acid, potassium oxalate,ferric oxalate, vitamin E, or a mixture thereof, and wherein thepreparation has the initial hardness of from 0.1 g to 20,000 g, measuredat Compression mode of Texture Analyzer (TA), at the time of attachment;and has the final hardness of 40,000 g or less, measured at Compressionmode of Texture Analyzer (TA), at the time of removal.
 2. Thepreparation of claim 1, wherein the active ingredient is mixed with theoral composition in a hardening ointment-phase and contained in thepreparation.
 3. The preparation of claim 1, wherein the preparationbecomes hardened and substantially loses its moldability in 5 minutes to3 hours after the preparation is attached to teeth or tooth peripheriesunder the humidity and temperature conditions of the oral cavity.
 4. Thepreparation of claim 3, wherein the becoming hardened and losing itsmoldability means that the preparation becomes to have a viscosity of5000 cps or higher, which is measured by using Brookfield viscometerequipped with No. 6, 7 spindles at 20° C., 5 to 20 rpm, in 5 minutes to3 hours after the preparation is attached to teeth or tooth peripheries.5. The preparation of claim 1, wherein the time of removal is when theamount of the active ingredient released into the oral cavity is 60 wt %or more, based on the amount of the active ingredient contained in theinitial preparation, after 30 minutes from the attachment of thepreparation to teeth or tooth peripheries.
 6. The preparation of claim1, wherein the preparation increases its area when the preparation ispressed by applying force at the beginning of attachment.
 7. Thepreparation of claim 1, wherein the preparation is one-formulation type;or two-formulation type consisting of the first formulation and thesecond formulation.
 8. The preparation of claim 1, wherein the oralcomposition in a hardening ointment-phase further comprises a materialfor helping drug release, and wherein the material for helping drugrelease includes at least one acid and at least one base, and whereinthe preparation is a two-formulation type consisting of a firstformulation containing the at least acid and a second formulationcontaining the at least one base.
 9. The preparation of claim 1, whereinwater-solubility of the preparation, measured at 32° C., 1 atm after 5minutes to 3 hours from attachment of the preparation to teeth or toothperipheries, is 20 wt % or less.
 10. The preparation of claim 1, whereinthe preparation further comprises a backing layer.
 11. A preparation forattaching to teeth or tooth peripheries, which comprises: a malleableoral composition; and an active ingredient for intra-oral delivery,wherein the malleable oral composition comprises a phase transitionmaterial, a phase transition auxiliary material, and anattachment-enhancing material of a phase transition composition, whereinthe phase transition material includes carrageenan, pectin, xyloglucan,gellan gum, ammonium alginate, magnesium alginate, potassium alginate,sodium alginate, lithium alginate, chitosan, poly-lactic acid(poly(D,L-lactic acid)), polylactide-co-glycolide(poly(DL-lactide-co-glycolide)), poly-caprolactone, polyacrylic acid(carbopol), polyvinylacetal diethyl aminoacetate (AEA),hydroxypropylmethyl cellulose, poly(methacrylic acid)-poly(ethyleneglycol), poly(D,L-lactide)-block-poly(ethyleneglycol)-block-poly(D,L-lactide), PEG-oligoglycolyl-acrylate,poly(N-isopropyl acrylamide), sucrose acetate isobutyrate, polyvinylalcohol, glyceryl monooleate, glyceryl monolinoleate, glycerylmonoarachidonate, glyceryl monostearate, or a mixture thereof, whereinthe phase transition auxiliary material includes a calcium ion source ofcalcium sulfate, calcium carbonate, calcium phosphate dibasic (CaHPO₄),barium carbonate, zinc carbonate, calcium chloride, calcium lactate,calcium citrate, calcium aspartate, calcium saccharate, calciumoxovalerate, calcium gluconate, calcium lactobionate or calciumlactogluconate; a chelating agent of barium carbonate, zinc carbonate,sodium bicarbonate, sodium carbonate, tetraborate or tripolyphosphate;acetic acid, malic acid, lactic acid, gluconic acid, ascorbic acid,boric acid or a mixture or a salt thereof; or NaOH, KOH or a mixturethereof, wherein the attachment-enhancing material of the phasetransition composition includes precipitated silica for thickening,colloidal silicone dioxide, polyvinyl pyrrolidone, poly methyl vinylether and maleic acid copolymer, shellac, rosin, poloxamer, hyaluronicacid, acrylate copolymer, hydroxypropyl methyl cellulose (HPMC),hydroxypropyl cellulose (HPC), polyacrylic acid, polyethylene glycol,ethyl cellulose or a mixture thereof, or a crosslinked body thereof,wherein the active ingredient is sodium fluoride, stannous fluoride,indium fluoride, amine fluoride, sodium monofluorophosphate, tetrasodiumpyrophosphate (TSPP), sodium acid pyrophosphate (SAPP), sodiumtripolyphosphate (STP), sodium potassium pyrophosphate, tetrapotassiumpyrophosphate, acidic sodium metaphosphate, acidic sodium polyphosphate,triclosan, chlorhexidine, alexidine, hexetidine, sanguinarine,benzalkonium chloride, salicylanilide, domiphen bromide, cetylpyridiniumchloride (CPC), tetradecylpyridinium chloride (TPC), aspirin, ketorolac,flurbiprofen, piroxicam, meclofenamic acid, thiamine, riboflavin,nicotinic acid, pantothenic acid, pyridoxine, biotin, folic acid,vitamin B12, lipoic acid, ascorbic acid, vitamin A, vitamin D, vitaminE, vitamin K, titrated extract of Zea Mays L. unsaponifiable fraction,Magnoliae Cortex, Myrrha, Rhatany, Chamomile, policresulen, titratedextract of Centella Asiatica, nutmeg extract, dexpanthenol,β-sitosterol, acetyl salicylic acid, zinc chloride, potassium phosphate,potassium diphosphate, calcium chloride, oxalic acid, potassium oxalate,ferric oxalate, vitamin E, or a mixture thereof, and wherein thepreparation has the initial compressibility of 0.1 to 30,000 gs,measured at Compression mode of Texture Analyzer (TA); and has the finalcompressibility of 50,000 gs or less, measured at Compression mode ofTexture Analyzer (TA).
 12. The preparation of claim 11, wherein theactive ingredient is mixed with the malleable oral composition anddispersed in the preparation.
 13. The preparation of claim 11, whereinthe time of removal is when the amount of the active ingredient releasedinto the oral cavity is 60 wt % or more, based on the amount of theactive ingredient contained in the initial preparation, after 30 minutesfrom the attachment of the preparation to teeth or tooth peripheries.14. The preparation of claim 11, wherein the preparation increases itsarea when the preparation is pressed by applying force at the beginningof attachment.
 15. The preparation of claim 11, wherein the malleableoral composition further comprises a material for helping drug release,and wherein the material for helping drug release includes at least oneacid and at least one base, and wherein the preparation is atwo-formulation type consisting of a first formulation containing the atleast acid and a second formulation containing the at least one base.16. The preparation of claim 11, wherein the preparation isone-formulation type; or two-formulation type consisting of the firstformulation and the second formulation.
 17. The preparation of claim 11,wherein the preparation becomes hardened and substantially loses itsmoldability in 5 minutes to 3 hours after the preparation is attached toteeth or tooth peripheries under the humidity and temperature conditionsof the oral cavity.
 18. The preparation of claim 17, wherein thebecoming hardened and losing its moldability means that the preparationbecomes to have a viscosity of 5000 cps or higher, which is measured byusing Brookfield viscometer equipped with No. 6, 7 spindles at 20° C., 5to 20 rpm, in 5 minutes to 3 hours after the preparation is attached toteeth or tooth peripheries.
 19. The preparation of claim 11, whereinwater-solubility of the preparation, measured at 32° C., 1 atm after 5minutes to 3 hours from attachment of the preparation to teeth or toothperipheries, is 20 wt % or less.
 20. The preparation of claim 11,wherein the preparation further comprises a backing layer.